NextCell Pharma AB (“NextCell” or “the Company”) is pleased to announce that its strategic collaboration with FUJIFILM Biosciences has been highlighted in an article published on 8 July by Genetic Engineering & Biotechnology News (GEN). The article covers FUJIFILM’s recent rebranding and long-term ambition to act as a full-spectrum partner to drug and vaccine developers throughout the entire development cycle.
The article, published by GEN – one of the top-ranked biotechnology industry publications, with a global readership of over 870,000 – recognises NextCell as part of FUJIFILM’s strategic transformation. The collaboration provides an integrated solution for researchers and developers in the cell therapy field, combining:
“Being featured in FUJIFILM’s broader strategic communication reinforces the significance of our collaboration,” said Mathias Svahn, CEO of NextCell. “It highlights our shared commitment to advancing cell therapy technologies through standardisation and scalability.”
GEN’s editorial coverage spans the full bioproduct life cycle, from early-stage research to commercialisation, and is followed by leading scientists, executives, and investors in the global biotech sector. Approximately 75% of its readership is based in the United States and 18% in Europe.
Recognition by GEN further underscores the growing importance of NextCell’s MSC platform within regenerative medicine and the next generation of biomanufacturing.
Read the full article here:
End-to-End: Fujifilm Rebrands Life Sciences Companies – GEN, 8 July 2025
For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com
Websites:
NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk
QVance AB: www.qvance.se
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye AB is assigned as Certified Adviser.
About NextCell Pharma AB
NextCell Pharma is a clinical-stage cell therapy company developing ProTrans, a patent-protected platform based on allogeneic mesenchymal stromal cells (MSCs) from umbilical cord tissue. Using a proprietary selection algorithm, ProTrans delivers optimised cell tailored to specific indications. In type 1 diabetes, a single infusion has been shown to preserve insulin production and delay disease progression for at least five years. A Phase III trial is planned to commence upon securing a commercial partner. ProTrans is also being evaluated for other autoimmune and inflammatory conditions. NextCell’s subsidiaries include Cellaviva, Scandinavia’s largest private stem cell bank, and QVance, the Nordic region’s first dedicated provider of quality services for developers of advanced therapies.